## Background: Gene therapy strategies for the treatment of vascular disease such as the prevention of post-angioplasty restenosis require efficient, non-toxic transfection of vascular cells. in vitro studies in these cells contribute to vector development for in vivo use and for the evaluation of
Optimization of in vitro vascular cell transfection with non-viral vectors for in vivo applications
✍ Scribed by Ibrahim Elmadbouh; Patrick Rossignol; Olivier Meilhac; Roger Vranckx; Chantal Pichon; Bruno Pouzet; Patrick Midoux; Jean-Baptiste Michel
- Publisher
- John Wiley and Sons
- Year
- 2004
- Tongue
- English
- Weight
- 485 KB
- Volume
- 6
- Category
- Article
- ISSN
- 1099-498X
- DOI
- 10.1002/jgm.604
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
Background
Syngeneic vascular cells are interesting tools for indirect gene therapy in the cardiovascular system. This study aims to optimize transfection conditions of primary cultures of vascular smooth muscle cells (VSMCs) using different non‐viral vectors and zinc as an adjuvant and to implant these transfected cells in vivo.
Methods
Non‐liposomal cationic vectors (FuGene™6), polyethylenimines (ExGen™500), and histidylated polylysine (HPL) were used as non‐viral vectors in vitro with secreted alkaline phosphatase (SEAP) as reporter gene. Transfection efficiency was compared in cultured rat, rabbit and human VSMCs and fibroblasts. Zinc chloride (ZnCl~2~) was added to optimize transfection of rat VSMCs in vitro which were then seeded in vivo.
Results
Much higher SEAP levels were obtained in rabbit cells with FuGene™6 (p < 0.0001) at day 2 than in equivalent rat and human cells. Rat VSMCs transfected in vitro with FuGene™6 and ExGen™500 expressed higher SEAP levels than with HPL. In rat VSMCs, SEAP secretion was more than doubled by addition of 250 µM ZnCl~2~ (p < 0.0001) for all vectors. Seeding of syngeneic VSMCs transfected under optimized conditions (FuGene™6/pcDNA3‐SEAP +250 µM ZnCl~2~) into healthy Lewis rats using various routes or into post‐infarct myocardial scar resulted in a peak of SEAP expression at day 2 and detectable activity in the plasma for at least 8 days.
Conclusions
FuGene™6 is an efficient non‐viral transfection reagent for gene transfer in somatic smooth muscle cells in vitro and ZnCl~2~ enhances its efficiency. This increased expression of the transgene product is maintained after seeding in vivo. Copyright © 2004 John Wiley & Sons, Ltd.
📜 SIMILAR VOLUMES
## Abstract ## Background The intercellular transport properties of the herpes simplex virus (HSV) protein VP22 have been harnessed to enhance the effectiveness of viral gene transfer. We investigated the intercellular transport and biological effects of VP22 fused with the dominant negative c‐Myb